Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate sodum (PPS) (now known as Zilosul) to market. It is…
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something to say about that.
You see, any ‘treatments’ that exist are…
Ageing population stocks represent among the best long-term opportunities that exist for investors.
Over the next 25 years, the world's population of people over 60 will double.
Looking specifically at Australia, the…